InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/09/2019

Re: None

Monday, 01/30/2023 10:24:15 AM

Monday, January 30, 2023 10:24:15 AM

Post# of 575
APTO announced the initiation of the APTIVATE trial today. I thought they initiated dosing in December. New response at 40mg is good news. The therapeutic window for Tuspetinib is very large which bodes well for combination studies. My only complaint is the slow pace.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News